Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 69655-05-6 | Product Number: D3066
2',3'-Dideoxyinosine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- ddI
- 9-(2,3-Dideoxy-β-D-ribofuranosyl)-6-oxopurine
- Didanosine
- 9-(2,3-Dideoxy-β-D-ribofuranosyl)hypoxanthine
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 100MG |
$33.00
|
2 | 1 | 1 |
|
| 500MG |
$132.00
|
1 | 1 | 4 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Supplemental Product Information:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
| Product Number | D3066 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__0H__1__2N__4O__3 = 236.23 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Hygroscopic |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 500MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 69655-05-6 |
| Reaxys Registry Number | 3619529 |
| PubChem Substance ID | 87559876 |
| SDBS (AIST Spectral DB) | 52174 |
| Merck Index (14) | 3098 |
| MDL Number | MFCD00077728 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | -26.0 to -30.0 deg(C=0.34, H2O) |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 182 °C |
| Specific Rotation | -28° (C=0.34,H2O) |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H373 : May cause damage to organs through prolonged or repeated exposure. H341 : Suspected of causing genetic defects. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | NM7460700 |
Transport Information:
| HS Number | 2934.99.4400 |
Application
Didanosine (ddI): A Nucleoside Reverse Transcriptase Inhibitor
2',3'-Dideoxyadenosine (ddA) [D3065] and didanosine (ddI) are nucleoside reverse transcriptase inhibitors. ddA is a synthetic nucleoside analogue of the naturally occurring nucleoside 2’-deoxyadenosine in which the 3'-hydroxyl group is replaced by hydrogen. Intracellularly, ddA and ddI are converted by cellular enzymes to the active metabolite, ddA- 5'-triphosphate. The triphosphate inhibits the activity of viral reverse transcriptase both by competing with the natural substrate, 2’-deoxyadenosine-5'-triphosphate, and by its incorporation into viral DNA causing termination of viral DNA chain. (The product is for research purpose only.)
References
- Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
- Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease
- Didanosine: an updated review of its use in HIV infection
- Didanosine enteric-coated capsule: current role in patients with HIV-1 infection
- Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.